Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992352 · ClinicalTrials.gov registry record
Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)
A clinical trial, sponsored by Center for International Blood and Marrow Transplant Research.
- Completed
- Registry status
- 1,229
- Enrollment target
NCT03992352: Completed study, sponsored by Center for International Blood and Marrow Transplant Research.
NCT03992352 is a clinical trial that has completed, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 1,229 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03992352 has completed, sponsored by Center for International Blood and Marrow Transplant Research.
- COMPLETED
- Registry status
- 1,229 participants
- Enrollment target
Study Summary
Prospective observational multicenter study of allogeneic Hematopoietic Stem Cell Transplantation (HCT) in recipients 60 years and older to assess important determinants of health status to be combined into a composite health risk model to improve risk assessment of non-relapse mortality (NRM).
Primary Outcome
To determine the set of assessments and biomarkers that could together constitute a robust and valid composite health risk model for accurate personalized estimation of NRM by analyzing data collected from all measures pre and post transplant.
Interventions
- DIAGNOSTIC_TEST Age 60+ with planned HCT for Hematologic Malignancy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,229 participants |
| Start Date | 2019-07-19 |
| Est. Completion | 2023-05-30 |
What the finished NCT03992352 record still lists
NCT03992352 is an observational study that tracks outcomes without assigning an intervention. Its 1,229 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Age 60+ with planned HCT for Hematologic Malignancy is the first listed.
NCT03992352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03992352 about?
NCT03992352 is a clinical study titled "Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)". Prospective observational multicenter study of allogeneic Hematopoietic Stem Cell Transplantation (HCT) in recipients 60 years and older to assess important determinants of health status to be combined into a composite health risk model to improve risk assessment of non-relapse mortality (NRM).
What is the current status of trial NCT03992352?
This trial is currently completed. The enrollment target is 1,229 participants. The study started on 2019-07-19. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT03992352?
The interventions under investigation include: Age 60+ with planned HCT for Hematologic Malignancy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03992352?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI